Showing 2021-2030 of 3223 results for "".
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies in Ophthalmic Diseaseshttps://modernod.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and
- President-Elect Biden Picks California Attorney General to Lead HHShttps://modernod.com/news/president-elect-biden-picks-california-attorney-general-to-lead-hhs/2478630/President-elect Joe Biden plans to nominate California Attorney General Xavier Becerra to lead the Department of Health and Human Services (HHS), according to
- Kerry Solomon First in US to Implant Alcon’s Vivity IOLhttps://modernod.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/Kerry Solomon, MD, partner at Carolina Eyecare Physicians, Charleston, South Carolina, is the first in the United States following FDA approval to complete surgery using Alcon’s AcrySof IQ Vivity Extended Range of Vision IOL, according to a news release. “The Vivity lens is a remarka
- Alcon Canada to Launch a Professional Line of Systane Ultra Hydration Lubricant Eye Drops Preservative Freehttps://modernod.com/news/alcon-canada-to-launch-a-professional-line-of-systane-ultra-hydration-lubricant-eye-drops-preservative-free/2478607/Alcon announced the Canadian launch of the newest addition to its portfolio of dry eye products—a professional line of Systane Ultra Hydration Lubricant Eye Drops Preservative Free. These new eye drops contain both hyaluronic acid (HA) and HP-Guar, a combination of ingredients shown to offer long
- Alcon Joins Health Care Alliance for Patient Safetyhttps://modernod.com/news/alcon-joins-health-care-alliance-for-patient-safety/2478602/The Health Care Alliance for Patient Safety (APS) announced Alcon as its newest member. “APS partners and patient safety advocates are excited to have Alcon join our effort to advance patient safety and strengthen the doctor-patient relationship, which is the foundation of personalized hea
- Eluminex Biosciences Announces Closing of $50 Million Series A Financinghttps://modernod.com/news/eluminex-biosciences-announces-closing-of-50-million-series-a-financing/2478597/China-based Eluminex Biosciences announced the completion of a $50 million Series A Financing, which will be used to develop a pipeline addressing critical unmet medical needs in vision-threatening diseases for patients. The financing was co-led by Lilly Asia
- CORE and Myopia Profile Form Alliance to Expand Clinical Research and Professional Education Capabilitieshttps://modernod.com/news/core-and-myopia-profile-form-alliance-to-expand-clinical-research-and-professional-education-capabilities/2478595/The Centre for Ocular Research & Education (CORE) and Myopia Profile announced an alliance designed to expand both organizations’ services and reach. The affiliation aims to grow CORE’s extensive clinical research capabilities, adding expertise in specialty lenses, gas permeable, orthokerato
- Alcon Canada Introduces AcrySof IQ Vivity Presbyopia-Correcting IOLhttps://modernod.com/news/alcon-canada-introduces-acrysof-iq-vivity-presbyopia-correcting-iol/2478568/Alcon has announced the Canadian launch of AcrySof IQ Vivity presbyopia-correcting IOL. AcrySof IQ Vivity uses a non-diffractive design called X-WAVE technology and provides an extended range of vision and reduced dependency on glasses following cataract surgery.
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-